Evidence-Based and Clinically Relevant Outcomes for Hemorrhage Control Trauma Trials.
Abstract | OBJECTIVE: BACKGROUND: A standardized primary outcome in clinical trials evaluating hemostatic products and strategies for the treatment of clinically significant bleeding will facilitate the conduct, interpretation, and translation into clinical practice of hemostasis research and support alignment among funders, investigators, clinicians, and regulators. METHODS: An international panel of experts was convened by the National Heart Lung and Blood Institute and the United States Department of Defense on September 23 and 24, 2019. For patients suffering hemorrhagic shock, the 26 trauma working-group members met for almost a year, utilizing biweekly phone conferences and then an in-person meeting, evaluating the strengths and weaknesses of previous high quality studies. The selection of the recommended primary outcome was guided by goals of patient-centeredness, expected or demonstrated sensitivity to beneficial treatment effects, biologic plausibility, clinical and logistical feasibility, and broad applicability. CONCLUSIONS: For patients suffering hemorrhagic shock, and especially from truncal hemorrhage, the recommended primary outcome was 3 to 6-hour all-cause mortality, chosen to coincide with the physiology of hemorrhagic death and to avoid bias from competing risks. Particular attention was recommended to injury and treatment time, as well as robust assessments of multiple safety related outcomes.
|
Authors | John B Holcomb, Ernest E Moore, Jason L Sperry, Jan O Jansen, Martin A Schreiber, Deborah J Del Junco, Philip C Spinella, Angela Sauaia, Karim Brohi, Eileen M Bulger, Andrew P Cap, John R Hess, Donald Jenkins, Roger J Lewis, Matthew D Neal, Craig Newgard, Shibani Pati, Anthony E Pusateri, Sandro Rizoli, Robert T Russell, Stacy A Shackelford, Deborah M Stein, Marie E Steiner, Henry Wang, Kevin R Ward, Pampee Young |
Journal | Annals of surgery
(Ann Surg)
Vol. 273
Issue 3
Pg. 395-401
(03 01 2021)
ISSN: 1528-1140 [Electronic] United States |
PMID | 33065652
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. |
Chemical References |
|
Topics |
- Clinical Trials as Topic
- Consensus
- Evidence-Based Medicine
- Hemostasis, Surgical
(methods)
- Hemostatics
(therapeutic use)
- Humans
- Outcome Assessment, Health Care
- Patient-Centered Care
- Shock, Hemorrhagic
(etiology, mortality, prevention & control)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|